Biao Jin

Biao Jin

Auto-generated profile, based on publicly available information

Biao Jin

Department of Critical Care Medicine, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, CHN

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2019 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
DLDan Liu
Dan Liu
BJBiao Jin
Biao Jin
WCwei Chen
wei Chen
PYPeng Yun
Peng Yun
Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular outcomes associated with DPP-4 inhibitors versus non-DPP-4 inhibitor users. All English publications that compared the use of DPP-4 inhibitors and that reported cardiovascular outcomes in patients with T2DM were searched using specific terms. Studies were included if they satisfied the following inclusion criteria: They were randomized trials or observation cohorts/registries comparing DPP-4 inhibitors use in patients with T2DM; The studies included a large sample size of participants; And they reported cardiovascular outcomes as their main endpoints. RevMan 5.3 was used to analyze the data, and odds ratios (OR) with 95% confidence intervals (CI) were used to represent the results. A total number of 157,478 participants with T2DM were included. Seventy-six thousand and twenty six patients were assigned to the DPP-4 inhibitor group whereas 81,452 patients were assigned to the control group. Results of the current analysis showed that during a mean follow-up time period ranging from 52 to 152 weeks, the primary endpoint (cardiovascular death/non-fatal myocardial infarction (MI)/non-fatal stroke) was not significantly different in the treatment of T2DM patients with versus without DPP-4 inhibitors (OR: 0.95, 95% CI: 0.86–1.04; P = 0.26). Cardiovascular death (OR: 1.00, 95% CI: 0.90–1.10; P = 0.93), stroke (OR: 1.03, 95% CI: 0.89–1.18; P = 0.72), MI (OR: 0.97, 95% CI: 0.88–1.07; P = 0.59), all-cause mortality (OR: 0.84, 95% CI: 0.59–1.18; P = 0.31), hospitalization for cardiovascular complications (OR: 1.02, 95% CI: 0.96–1.09; P = 0.45) and hospitalization specifically for heart failure (OR: 1.05, 95% CI: 0.90–1.23; P = 0.55) were also similarly manifested in both groups. The current analysis showed that treatment with DPP-4 inhibitors did not significantly increase cardiovascular outcomes in these patients with T2DM indicating that those drugs might be safe to use in terms of cardiovascular events.

15 April 2021 in Cureus
Verified
Journal Article
Open access
YLYide Li
Yide Li
YSYINFANG She
YINFANG She
WMWeisheng Mo
Weisheng Mo
BJBiao Jin
Biao Jin
WXWendi Xiang
Wendi Xiang
YTYan Tang
Yan Tang
Cardiac arrest is a global health concern with consistently high mortality. It is also a common condition seen in the intensive care unit (ICU). We aimed to investigate the importance of albumin level on admission, which is a widely available and simple test, to predict in-hospital mortality in cardiac arrest patients. The retrospective study collected data from the eICU Collaborative Research Database. It contains data from 171 hospitals, 276 ICU wards, and 4,529 patients who were treated for cardiac arrest from 2014 to 2015. We analyzed the patients’ laboratory results and vital signs during the first 24 hours after admission to the ICU. The primary outcome was in-hospital mortality, and the secondary outcome was the length of ICU stay among survivors. In total, 2,414 patients were eligible. After adjusting for severity scores, including the Acute Physiology and Chronic Health Evaluation (APACHE) IV and Sequential Organ Failure Assessment (SOFA) scores, serum albumin was found to be a protective factor for survival (odds ratio of mortality: 0635, 95% confidence interval: 0.458-0.734, P<0.001). Among patients who survived until discharge, those with hypoalbuminemia had a long duration of stay in the ICU (P=0.005). The higher albumin level at admission to the ICU was associated with lower mortality in patients with cardiac arrest.